Abstract
Conditions of poor oxygenation (hypoxia) are present in the majority of solid human tumors and are associated with poor patient prognosis due to both hypoxia-mediated resistance to treatment, and to hypoxiainduced biological changes that promote increased malignancy, including metastasis. Tumor cells respond to hypoxia by activating several oxygen-sensitive signaling pathways that include the hypoxia inducible factor 1/2 (HIF1/2) signalling pathways and the unfolded protein response (UPR), which alter gene expression to promote adaptation and survival during hypoxic conditions. Furthermore, these hypoxia responsive pathways can lead to changes in gene expression and cellular phenotype that influence the potential of cancer cells to metastasize. However, the hypoxia-induced signaling events that promote tumor metastasis are still relatively poorly understood. Previous studies have largely focused on the contribution of the HIF signaling pathway to hypoxia-mediated metastasis. However, recent evidence demonstrates that hypoxic activation of the UPR is also an important mediator of metastasis.
Current Molecular Medicine
Title:Hypoxia Signaling and the Metastatic Phenotype
Volume: 14 Issue: 5
Author(s): H. Mujcic, R.P. Hill, M. Koritzinsky and B.G. Wouters
Affiliation:
Keywords: Cancer, HIF, hypoxia, LAMP3, metastasis, UPR.
Abstract: Conditions of poor oxygenation (hypoxia) are present in the majority of solid human tumors and are associated with poor patient prognosis due to both hypoxia-mediated resistance to treatment, and to hypoxiainduced biological changes that promote increased malignancy, including metastasis. Tumor cells respond to hypoxia by activating several oxygen-sensitive signaling pathways that include the hypoxia inducible factor 1/2 (HIF1/2) signalling pathways and the unfolded protein response (UPR), which alter gene expression to promote adaptation and survival during hypoxic conditions. Furthermore, these hypoxia responsive pathways can lead to changes in gene expression and cellular phenotype that influence the potential of cancer cells to metastasize. However, the hypoxia-induced signaling events that promote tumor metastasis are still relatively poorly understood. Previous studies have largely focused on the contribution of the HIF signaling pathway to hypoxia-mediated metastasis. However, recent evidence demonstrates that hypoxic activation of the UPR is also an important mediator of metastasis.
Export Options
About this article
Cite this article as:
Mujcic H., Hill R.P., Koritzinsky M. and Wouters B.G., Hypoxia Signaling and the Metastatic Phenotype, Current Molecular Medicine 2014; 14 (5) . https://dx.doi.org/10.2174/1566524014666140603115831
DOI https://dx.doi.org/10.2174/1566524014666140603115831 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Platelet Toll-Like Receptor Expression: The Link Between “Danger” Ligands and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Adrenergic and V1-ergic Agonists/Antagonists Affecting Recovery from Brain Trauma in the Lund Project Act on Astrocytes
Current Signal Transduction Therapy Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Current Pharmaceutical Biotechnology Rho Kinase: An Important Mediator of Atherosclerosis and Vascular Disease
Current Pharmaceutical Design Landmark-Based Shape Analysis on Middle Cerebral Intracranial Aneurysms: A Geometric Morphometrics Approach to Infer Natural History
Current Neurovascular Research Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Current Alzheimer Research Current Evidence for Antithrombotic Therapy after Peripheral Vascular Interventions
Current Vascular Pharmacology Bioactive Peptides in Preventative Healthcare: An Overview of Bioactivities and Suggested Methods to Assess Potential Applications
Current Pharmaceutical Design Extracts and Flavonoids of <i>Passiflora</i> Species as Promising Anti-inflammatory and Antioxidant Substances
Current Pharmaceutical Design Bioactive Compound and Nanotechnology: A Novel Delivery Perspective for Diabetic Retinopathy
Current Bioactive Compounds Chymase Inhibitors
Current Pharmaceutical Design Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies
Current Drug Delivery Early Brain Injury or Vasospasm? An Overview of Common Mechanisms
Current Drug Targets Using Extracellular Matrix-Derived Peptides to Alter the Microenvironment for Myocardial Repair
Current Vascular Pharmacology Targeting the Role of Lipoprotein (a) in Stroke
Cardiovascular & Hematological Disorders-Drug Targets Red Wine, Arterial Stiffness and Central Hemodynamics
Current Pharmaceutical Design MicroRNAs in Arterial Remodelling, Inflammation and Atherosclerosis
Current Drug Targets Statins: A Valuable Tool for the Prevention/Regression of Abdominal Aortic Aneurysms
Vascular Disease Prevention (Discontinued) Genetic and Molecular Determinants of Atherosclerotic Plaque Instability
Current Vascular Pharmacology